How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and resource savings reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B‑cell lymphoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about polatuzumab vedotin

Marketing authorisation indication

2.1 Polatuzumab vedotin (Polivy, Roche) in combination with bendamustine and rituximab has a conditional marketing authorisation for 'the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant'.

Dosage in the marketing authorisation

2.2 The recommended dose of polatuzumab vedotin is 1.8 mg per kg, given as intravenous infusion every 21 days in combination with bendamustine and rituximab for 6 cycles. When administered with polatuzumab vedotin, the recommended dose of bendamustine is 90 mg per m2 per day on day 1 and day 2 of each cycle and the recommended dose of rituximab is 375 mg per m2 on day 1 of each cycle. It is recommended that polatuzumab vedotin does not exceed the dose of 240 mg per cycle.

Price

2.3 The cost per item from the company's submission is £11,060 per 140‑mg vial (excluding VAT). The company estimates that the average cost of a course of treatment is £50,416.

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.